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Extrapolation from Incomplete Data to
Total or Lifetime Risks at Low Doses
by Marvin A. Schneiderman*
Both epidemiology and laboratory data can contribute to estimates of risks to humans of
exposure to low doses of carcinogens. The sum of all these contributions does not permit us to
make these estimates with certainty. In chronic disease epidemiology, in looking for possible
excessive cancer risks, we sometimes fail to have an adequately long observation time or to
observe a population sufficiently aged for cancers to appear in meaningful numbers. In studies
of most human exposures, dose data are often lacking, beyond a vague "yes-no" or "lots, not
much, hardly any." Thus, without a knowledge of what dose produced an observed result it
becomes logically impossible to know what result some other (presumed) dose might yield.
Animal data show some promise of being useful in extrapolating to low doses in man.
However, several problems exist: (a) man is not a tailless, two-legged mouse, or featherless
chicken-that is, we do not know if man is more or less sensitive than the laboratory animal;
(b) the mathematical model used for extrapolation leads to large differences in estimates of
response; (c) man is genetically heterogeneous and is usually exposed to many more hazards
than is the laboratory animal.
Thus, existing data, even from well-done studies, are inadequate if we want to make
extrapolations in any detail or to apply to specific subgroups in the population. Any risk
estimation we do may have to be stated in terms that point out the wide ranges ofthe estimates.
The theme ofthis paper derives from the lines in
the spiritual that say, "Nobody knows all the
troubles I've seen. Nobody knows but Jesus." I
would claim this as my personal lament, except for
the fact that I know that anyone who has at-
tempted to conduct studies in the epidemiology of
cancer shares it with me.
The issues as I see them are these: (1) What can
we learn (or infer) about some humans from
observing other humans living under different
circumstances? (2) What can we learn (or infer)
about humans, in general, from observing other
mammals, or birds, or fish, or tissues, or cells, or
subcellular particles?
The answer to both these questions is "a lot, but
not nearly enough." The major problem that I see
is an "incomplete data" problem and that comes, in
large part, from our impatience. We want answers
about lifetime effects from less than lifetime ob-
servations. We are not in the position of the
materials testing engineers who can do accelerated
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life testing. We may speak ofburning the candle at
both ends, but we cannot speed up the life process
for testing purposes in humans. If"senility" occurs
in 20% of all persons 80 years old or over we do
not think we will find 2% of 8-year-olds showing
senility. Yet sometimes all our person-years of
observation help us forget that biological processes
ranging from pregnancy to cancer to senility have
a minimum "maturation time." We know that nine
women one month pregnant do not equal one
woman pregnant nine months. Sometimes we for-
get that observing 400 people for one year when
we are concerned with cancer may give us much
less information than observing 20 persons for 20
years. Since I am concerned with cancer, I must
deal with this maturation phenomenon. If the
median age at diagnosis of bladder cancer is 68
years, I will be most unlikely to find anything of
consequence in any current study about cancer in
the "second generation" children now age 10-15
who are consumers of "diet" drinks, and whose
mothers were also consumers of "diet" drinks. In
fact we are scarcely likely to learn anything much
about the mothers and cancer, considering when
33the large increases in the use of artificial sweeten-
ers first started in this country.
We are concerned here today with dose-response
phenomena, and I will try to deal largely with
that. An obvious early question one asks about
dose-response phenomenon in man is, "Is there a
safe level?" This is another way of asking the
question, "Is there a threshold for a carcinogen?"
About two years ago, Charles Brown, Pierre
Decoufle, and I assembled some evidence on this
issue (1). Decoufle reviewed ten published occupa-
tional studies reported to have yielded "negative"
results, i.e., to have demonstrated a threshold at
the highest doses. He assembled some background
data on these studies. These serve as examples of
some of the problems epidemiologic studies can
run into. Table 1 gives some characteristics of
these studies.
The major deficiencies, or complaints of de-
vidiencies, are obvious. Almost all the studies
were short and thus did not allow for latent
periods in cancer or were based on too young a
population-a population unlikely to show any but
very large effects-or there was dilution of the
exposed group by a large number of (presumed)
unexposed persons, or the authors really didn't
know who was exposed or to how much. If these
Table 1. Characteristics of some "negative" occupational
epidemiology (cancer) studies.
No. of
Characteristic studies
Nature of study
Retrospective cohort 6
Forward cohort 0
Cross-sectional 3
Proportionate mortality 2
lla
Nature of exposure
Well defined (individual dose) 0
Some estimate (e.g. duration ofemployment)
(general air levels) 4
Poorly defined:
(a) yes-no only 1
(b) presumptive only 5
10
Methodology problems
Incomplete death reporting 1
Errors in cause-of-death 1
Young cohort 4
Short follow-up 3
Inappropriate group followed (dilution) 3
Small numbers 3
Identification problems 1
16b
aOne study in two categories.
bSeveral studies had more than one defect.
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are common deficiencies in published studies as-
serting no effect, it is understandable that the
Occupational Safety and Health Administration (2)
should lay out rather rigid standards for accep-
tance of what they refer to as nonpositive
epidemiologic studies: "The epidemiologic study
involved at least 20 years' exposure of a group of
subjects to the substance and at least 30 years'
observation of the subjects after initial exposure;"
"The group of exposed subjects was large enough
for an increase in cancer incidence of 50% above
that in unexposed controls to have been detected
at any ofthe predicted sites."
OSHA (2) supports these minimum 20-30 cri-
teria by testimony from Richard Peto, Irving
Selikoff, David Rall, Robert Hoover and John
Berg, among others. The 50% criterion is further
constrained in these remarks ". . . in theory, at
least, an epidemiologic study must be sensitive
enough to detect a 50% increase ... at any site....
In practice, such a criterion could not be used,
because no epidemiologic study of practical size
could detect a 50% increase in a rare type of
tumor. Thus OSHA is willing for practical reasons
to consider studies which are sensitive enough to
detect a 50% increase at all sites where the agent
is judged likely to act in humans."
In at least one sense, this is a weak criterion.
An excess risk of 50% is hardly trivial. However
"to require greater sensitivity would place unrea-
sonable demands ...." (2).
Dose-Response Phenomena
Decoufles comments on the paucity or the
inadequacy of dose data in putative, "negative"
industrial epidemiology studies (1) apply almost as
well to so-called positive studies. Rarely are there
data on individual exposures. Rarely does one
meet the 20-30 criteria. Yet, if positive results
appear, clearly one need not wait for the 20-30
phenomenon. It is not that different levels ofproof
are demanded, but rather that the perceptions of
"positive" and negative, must of necessity be
different. "Positive" is taken to mean positive at
any time, while "negative" is taken to mean
negative at all times.
Ifwe came to the conclusion that we have seen a
positive result, i.e., that there is a relationship
between some exposure and the appearance of
disease, the immediate question that follows is
"how much?" That is, we want the answer to the
question "How many units of disease will be
produced by adding X units of exposure?" Unfor-
tunately, the question is almost unanswerable,
because most of the time we do not know what a
Environmental Health Perspectives"unit of exposure" is. Nonetheless, it is worth
looking at some data that have been compiled
relating exposures to consequences. I will mention
the industrial data, mostly to point out problems,
but these will be dealt with much more fully in the
paper that follows by Professor Enterline. The
major studies in which we have dose-response
relationships in humans are the radiation studies
from Hiroshima and Nagasaki (3) with which Dr.
Land is most conversant, or among uranium min-
ers (4, 5), the smoking and lung cancer studies of
Doll et al. (6), Hammond and Horn (7), and Dorn
(8) and the studies ofasbestos workers by Enterline
(9) and McDonald (10). There are others, but these
are enough to make the point at this time.
The radiation studies point up the problems
most clearly, because we know most about radiation
carcinogenesis and what we know is not enough.
Having agreed that ionizing radiation is cancer-
producing, we are immediately beset by problems
in characterizing how carcinogenic. We recognize
differences between high LET radiation and low
LET radiation. We are uncertain about the effects
of dose rate; we are even less certain about the
joint effects of radiation and exposure to other
identified carcinogenic activity. We have seen
radiation carcinogenesis arising out ofthe one-time
exposures (at high dose, to many people, at least)
at Hiroshima and Nagasaki, and we have seen
radiation carcinogenesis in chronically exposed radi-
ologists. The dose-response relationships that many
of us considered "conservative," the linear, no-
threshold concepts are being challenged on both
sides as both overstating and understating the
risks.
What happens when we look into other physical
carcinogens, and the (more likely) more compli-
cated area of chemical carcinogens? The earlier
work by Enterline and McDonald on cancer follow-
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ing asbestos exposures led them to consider seri-
ously the possible existence of threshold and
apparently did not lead them to any serious
attempts at dose-response curve-fitting. I made
some crude attempts (11) to bring their two sets of
data together, and to try some curve-fitting (which
I did not quantify). I saw less reason to believe
there was a threshold when I looked at the data
for lung cancer than when I looked at the data for
the digestive system cancers (Figs. 1 and 2).
More recent (and more sophisticated) work by
Enterline (12) and by Liddell in cooperation with
McDonald (13) have led to curve fitting and dose-
response curves. Both of these attempts have led
to linear dose-response equations, Enterline's giv-
ing a response in respiratory cancer against cumu-
lative dust exposure (mppcf-years) that led him to
the equation (1):
Predicted SMR =
100.0 + 0.658 cumulative exposure
and this remark, "[it is] remarkable that this
empirical fit gives a y intercept of 100." He also
notes small changes over two time periods (1941-69,
compared to 1970-73), and concludes with this
cautionary remark: "The numbers are much too
small to speculate on the form this relationship
takes [in recent times], however."
The Liddell data can also be fitted by a straight
line (these data relate to Quebec asbestos miners).
Liddell gives his results in terms of relative risk
per mppcf-years. My fitting of the data yields the
equation (2):
RR = 1 + 2.8 x 0l mppcf-years
which is substantially shallower than Enterline's
"predicted curve"; i.e., it predicts lower risks at
the low doses.
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FIGURE 1. Cancer among workers exposed to asbestos: lung
cancer.
December 1981
Dose Mtpft -Years (Lag Scale)
FIGURE 2. Cancer among workers exposed to asbestos: diges-
tive tract cancers.
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WThe different slopes raise very serious questions
about what data can, or should, be used for
prediction. Enterline points out, as do others, that
the type of asbestos, and the conditions of work
(whether exposure was intermittent or continuous)
led to different SMR's for respiratory cancer.
Cornfield (14, 15) has shown that problems in the
accurate measurement of doses and of response
can lead to apparent linearity of what is truly a
curvilinear response. Doll and Peto (16) re-examined
the dose-response relationship in cigarette smok-
ing and lung cancer (annual incidence rates of
bronchiogenic cancer as related to dose and dura-
tion of exposures) and found that when various
possible biases in reporting were removed, there
was evidence for a distinct turning upward of the
dose-response curve at the higher dose levels. This
turning upward is consistent with a multistage
hypothesis of cancer induction. At low doses,
however, the linear term dominates.
The Doll-Peto re-examination of the smoking
data points to an important area ofneeded interac-
tion or interface. The mathematical models of
dose-response must be consistent with the biologi-
cal models of how the disease comes about. Thus,
the Doll-Peto finding of (mild) positive curilinearity
is consistent with the multistage model of cancer
induction. This, of course, is only a first step in
developing an appropriate prediction model since
few, ifany, ofthe models have yet built into them
dose rates, duration of exposure, effects of cessa-
tion of exposure, age of the exposed persons,
competing risks, etc.
One of the more recent attempts at extending
the multistage model concept is a paper by Day
and Brown (17) which considers the effects of
stopping exposure. Their major finding is that the
effect depends upon the stage in the multi-stage
process which the carcinogen predominantly ef-
fects. They confirm the concern often expressed
about the utility of human data as a means to
prevention. They write ". . . by the time the
human evidence that a hazard does exist becomes
available, those already exposed may well have
accumulated their fully effective dose."
The Day-Brown results have shown that the
effect of exposures to early stage carcinogens is
acquired in a relatively short time and then does
not diminish rapidly, even after cessation of expo-
sure. For example, for a first-stage exposure at
age 40, five years of exposure would, by their
calculations, produce 44% of the effect (excess
cancer risk over background) that a "remaining
life-time" ofexposure would produce. On the other
hand, similar five-year exposure to a penultimate
stage carcinogen would give 11% of the excess
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cancer risk over background compared to a re-
maining life-time exposure.
These results have serious implications for ex-
trapolation and for further experimentation; i.e.,
in attempts to identify where in the carcinogenic
process a material fits and to identify materials
other than complete carcinogens. I see the
Brown-Day results as a possible unifying force in
helping sort out initiators, promoters, pro-
carcinogens, proto-carcinogens, facilitators, etc.,
etc. The Brown-Day results lend support to the
suggestion that the control of late stage carcino-
gens can lead to relatively rapid decline in cancer
rates. Continuing exposures to late stage carcino-
gens appears to be necessary until an irreversible
cancer process is triggered. Ending this exposure
should interrupt the process, so that, unless a
preclinical cancer has already developed, cancer
will then not develop. The experience with endo-
metrial cancers and post-menopausal estrogens is
consistent with this formulation of the cancer
process. Day and Brown do not find it necessary to
postulate the existence of thresholds for "promot-
ers" to explain this behavior of late stage carcino-
gens.
Thus, we find such factors as type of radiation
(high LET vs. low LET), type of asbestos (e.g.,
chrysotile, crocidolite, etc.), nature of exposure
(intermittent vs. continuous), duration of expo-
sure, effect of other exposures, effect of cessation
of exposure all possibly modifying the dose-
response curves and we have little way to take
them into account. The human data rarely come in
enough quantity and enough detail to allow us to
do much more than describe a given situation, and
that usually incompletely. When we want to take
important details into account when forecasting
what will happen, we rarely, ifever, have the data
upon which to do it.
If our human data are so incomplete, we can
have the hope that data from animal experimenta-
tion may fill the gap. In a sense, the mouse with
the two to three year life-span may possibly
supply the equivalent ofaccelerated life testing for
man. David Rall recently wrote a succinct sum-
mary ofthe place ofanimal experiments in toxicity
testing (18). The question he sees is this: "We are
dealing here with large human populations with
relatively small differences in exposure . . . . Can
we use experiments with laboratory animals to
project what is likely to happen in the human
population?"
There is substantial dose-response data in ani-
mals so that if we were concerned with making
estimates ofthe risks at low doses for some strains
ofmice or rats we might do moderately well. Ifwe
Environmental Health Perspectiveswant to go from mouse to man, we're on much
shakier ground. Rall gives a table (Table 2) cover-
ing all the known carcinogens for which there are
both human and animal dose-response data (from
an NAS/NRC study on pest control practices).
This table was constructed with doses compared
on a milligram per kilogram basis. The compari-
sons were not as close when attempts were made
to extrapolate on a surface-area basis, which, for
certain other comparisons, seems to give much
closer correspondence between human and animal
responses.
The correct measure of dose in moving from one
species to another is of some consequence. It has
been looked at from time-to-time, but no simple
solution seems to be at hand. As an example ofthe
difficulties, Table 3, derived from the NRC/NAS
review of the saccharin issue (19) is worth looking
at. Two points thrust themselves at us from this
table. First, the model makes an enormous differ-
ence. The range of estimates from model to model
is about 5 x 106. Models will have to bejustified on
their biology, notjust their goodness offit. Second
the dose-metameter is important, even within the
same model. There is a 200-fold difference within
the Mantel-Bryan scheme, for example, ifone uses
mg/kg/day vs. mg/kg/lifetime.
Table 2.
Predicted human incidence based
on most sensitive animal species
Material relative to epidemiologic studies
Full data available
Benzidine Same
Chlornophthazine Same
Cigarette smoke Same
Aflatoxin B1 10 x greater
Population still at risk
DES 50 x greater
Vinyl chloride 500 x greater
Table 3. Estimated human risks from saccharin ingestion of
0.12 g/day (lifetime cases per million exposed).a
Dose measure (rats to humans)
Surface Mg/kg/ Mg/kg/
Extrapolation method area day lifetime
One-hit (Hoel et al.) 1,200 210 5,200
Multi-hit (Food
Safety Council) 0.001 0.001 0.001
Multistage
(Brown et al.) 5 Not done Not done
Probit (Mantel-Bryan) 450 21 4,200
aThis table points out the two important problems in extrapo-
lation: choice ofthe mathematical model, and choice ofthe dose
metameter.
Thus, we find ourselves trying to estimate what
will happen to people who are exposed to low
doses of materials that we have previously shown
to be toxic either to other humans, at much higher
doses, or to animals. The issue is how we can use
these high-dose data and/or these animal data to
help us estimate what might happen at lower
doses and under different circumstances. For this
I see three principles emerging.
(1) Existing data even from well-done studies
are inadequate if we want to make our extrapola-
tions in any detail or to apply to specific subgroups
in the population. Any risk estimation we do may
have to be stated in terms that point out the wide
ranges our estimates lead to.
(2) Experimental or epidemiologic studies are of
themselves not sufficient. They need to be tied in
with appropriate biological models of the diseases
we are concerned with and these, in turn, must
derive from other research.
(3) Principles of careful epidemiologic work and
careful laboratory work will have to be carefully
adhered to. The too small study, with the too short
follow up, with the too little dosage information is
too poor to use for risk estimation.
Public, political, and economic pressures will
push us into making risk estimates. If we make it
clear how poor these estimates can be perhaps we
can push ourselves and our colleagues into doing
better studies, and building biologically better
models that might, sometime in the future, give us
good enough risk estimates, so that political deci-
sions can be made from them with some confidence.
That day is not here yet.
REFERENCES
1. Schneiderman, M. A., Decoufle, P., and Brown, C. C.
Thresholds for environmental cancer: biological and statis-
tical considerations. Ann. N.Y. Acad. Sci. 329: 92-130
(1979).
2. Department of Labor, Occupational Safety and Health
Administration. Identification, classification and regulation
of potential occupational carcinogens. Federal Register
45(15): 5050-5060 (Jan. 22, 1980).
3. Land, C. E., and McGregor, D. H. Dose-response relation-
ship in radiogenic breast cancer. J. Natl. Cancer Inst. 60:
728-729 (1978).
4. Jablon, S. Environmental factors in cancer induction:
appraisal of epidemiologic evidence for leukemia, lympho-
ma, and radiation. In: Cancer Epidemiology, Environmen-
tal Factors, P. Bucalossi, Ed., American Elsevier, New
York, 1975, pp. 239-243.
5. Lundin, F. E., Jr., Wagoner, J. K., and Archer, V. E.
Radon Daughter Exposure and Respiratory Cancer: Quan-
titative and Temporal Aspects. National Institute for
Occupational Safety and Health, National Institute of
Environmental Health Sciences Joint Monograph 1, U.S.
DHEW, Washington, D.C., 1971.
6. Doll, R., and Peto, R. Mortality in relation to smoking: 20
December 1981 37years' observations on male British doctors. Brit. Med. J.
2: 1525 (1976).
7. Hammond, E. C., and Horn, D. Tobacco and lung cancer.
Proceedings of the Second National Cancer Conference,
1952, pp. 871-874.
8. Dorn, H. F. The increase in cancer of the lung. Ind. Med.
Surg. 23(6): 253-257 (1954).
9. Enterline, P., Decoufle, P., and Henderson, V. Respira-
tory cancer in relation to occupational exposures among
retired asbestos workers. Brit. J. Ind. Med. 30: 162-166
(1973).
10. McDonald, J. C. Cancer in chrysotile mines and mills.
Paper presented at Conference on Biological Effects of
Asbestos, Lyon, France, 1972.
11. Schneiderman, M. A. Digestive system cancer among
persons subjected to occupational inhalation of asbestos
particles: a literature review with emphasis on dose re-
sponse. Environ. Health Perspect. 9: 307-311 (1974).
12. Enterline, P. Asbestos exposure: factors associated with
excess cancer and respiratory disease mortality. Ann. N.Y.
Acad. Sci. 330: 117-126 (1979).
13. Liddell, F. D. K., McDonald, J. C., and Thomas, D. C.
Methods of cohort analysis: appraisal by application to
asbestos mining. J. Roy. Statist. Soc. A140(4): 469-491
(1977).
14. Cornfield, J. Carcinogenic risk assessment. Science 198:
683 (1977).
15. Cornfield, J., Carlborg, F. W., and Van Ryzin, J. Setting
tolerances on the basis of mathematical treatment of
dose-response data extrapolated to low doses. Proceedings
ofthe 1st International Congress on Toxicology, G. L. Plaa
and W. A. M. Duncan, Eds., Academic Press, New York,
1978, pp. 143-163.
16. Doll, R., and Peto, R. Cigarette smoking and bronchial
carcinoma: dose and time relationships among regular
smokers and life-long non-smokers. J. Epidemiol. Commun.
Health 32: 303-313 (1978).
17. Day, N. E., and Brown, C. C. Multistage models and the
primary prevention of cancer. J. Natl. Cancer Inst. 64:
977-989 (1980).
18. Rall, D. P. Relevance of animal experiments to humans.
Environ. Health Perspect. 32: 297-300 (1979).
19. NAS. Saccharin: Technical Assessment of Risks and Be-
nefits. Report No. 1. Committee for a Study on Saccharin
and Food Safety Policy. National Academy of Sciences,
Washington, D.C., 1978.
38 Environmental Health Perspectives